CISH knockout results in enhanced tumor reactivity and cytokine production in TILs and is currently undergoing evaluation in two clinical trials (NCT05566223 and NCT04426669).[143] The gene fusion of CARD11‐PIK3R3, discovered in cutaneous T cell lymphoma, is reported to amplify CARD11‐BCL10‐MALT1 complex signaling and increase the anti‐tumor potential of T cells. Here, CARD11 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.